tiprankstipranks
Trending News
More News >
Isofol Medical AB (DE:5IU)
FRANKFURT:5IU
Advertisement

Isofol Medical AB (5IU) Price & Analysis

Compare
2 Followers

5IU Stock Chart & Stats


Isofol Medical AB News

5IU FAQ

What was Isofol Medical AB’s price range in the past 12 months?
Isofol Medical AB lowest stock price was €0.05 and its highest was €0.30 in the past 12 months.
    What is Isofol Medical AB’s market cap?
    Isofol Medical AB’s market cap is €20.82M.
      When is Isofol Medical AB’s upcoming earnings report date?
      Isofol Medical AB’s upcoming earnings report date is Nov 12, 2025 which is in 64 days.
        How were Isofol Medical AB’s earnings last quarter?
        Isofol Medical AB released its earnings results on Aug 21, 2025. The company reported -€0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.008.
          Is Isofol Medical AB overvalued?
          According to Wall Street analysts Isofol Medical AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Isofol Medical AB pay dividends?
            Isofol Medical AB does not currently pay dividends.
            What is Isofol Medical AB’s EPS estimate?
            Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Isofol Medical AB have?
            Isofol Medical AB has 281,107,240 shares outstanding.
              What happened to Isofol Medical AB’s price movement after its last earnings report?
              Isofol Medical AB reported an EPS of -€0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Isofol Medical AB?
                Currently, no hedge funds are holding shares in DE:5IU

                Company Description

                Isofol Medical AB

                Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.

                Isofol Medical AB (5IU) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                Xintela AB
                IRLAB Therapeutics AB Class A
                Modus Therapeutics Holding AB
                Active Biotech AB
                Bio-Works Technologies AB
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis